Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075

Benzinga · 6d ago
Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $900 to $1075.